DOI: 10.1097/rlu.0000000000006726 ISSN: 0363-9762
Amyloid PET Changes During Lecanemab Treatment in Patients With and Without Amyloid-related Imaging Abnormalities
Yaqin Guo, Qiuyu Ji, Yang Yang, Meng Liang, Zhifang WuLecanemab reduces cerebral amyloid-β burden in Alzheimer disease, but whether amyloid-related imaging abnormalities (ARIA) are associated with greater amyloid clearance remains unclear. We report 3 patients with comparable clinical backgrounds and similar baseline cognitive performance who underwent amyloid-β PET before and after lecanemab treatment. Quantitative analysis using Centiloid showed a greater reduction in amyloid burden in the patient who developed ARIA than in the 2 patients without ARIA. These observations suggest ARIA may be associated with more pronounced treatment-related amyloid clearance, warranting further investigation in larger cohorts.